Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia‐bearing mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Current leukaemia therapy focuses on increasing chemotherapy efficacy. Mesenchymal stromal cells (MSC s) have been proposed for carrying and delivery drugs to improve killing of cancer cells. We have shown that MSC s loaded with Paclitaxel (PTX) acquire a potent anti‐tumour activity. We investigated the effect of human MSC s (hMSC s) and mouse SR 4987 loaded with PTX (hMSCsPTX and SR 4987 PTX) on MOLT‐4 and L 1210, two leukaemia cell (LCs) lines of human and mouse origin, respectively. SR 4987 PTX and hMSCsPTX showed strong anti‐LC activity. hMSCsPTX, co‐injected with MOLT‐4 cells or intra‐tumour injected into established subcutaneous MOLT‐4 nodules, strongly inhibited growth and angiogenesis. In BDF 1‐mice‐bearing L 1210, the intraperitoneal administration of SR 4987 PTX doubled mouse survival time. In vitro, both hMSC s and hMSCsPTX released chemotactic factors, bound and formed rosettes with LC s. In ultrastructural analysis of rosettes, hMSCsPTX showed no morphological alterations while the attached LC s were apoptotic and necrotic. hMSC s and hMSCsPTX released molecules that reduced LC adhesion to microvascular endothelium (hMEC s) and down‐modulated ICAM 1 and VCAM 1 on hMEC s. Priming hMSC s with PTX is a simple procedure that does not require any genetic cell manipulation. Once the effectiveness of hMSCsPTX on established cancers in mice is proven, this procedure could be proposed for leukaemia therapy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600 · cited 1×
“…the capacity, under particular culture conditions, to uptake and subsequently release significant amounts of Paclitaxel (PTX), a drug with antiproliferative and anti-angiogenic properties that is widely used for the chemotherapy of different human cancers (Schiff et al, 1979; Belotti et al, 1996).”
BackgroundA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“The murine MSCs line SR4987 was established in our laboratory (Pessina et al, 1992; Dull et al, 1998; Falchetti et al, 2008) (see Supporting Information).”
BackgroundKlopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 2×
“The capacity of MSCs, when added exogenously, to inhibit tumour growth is still under debate (Klopp et al, 2011).”
BackgroundRamasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404 · cited 1×
“It has been shown that in vitro, MSCs may secrete molecules that could inhibit LCs proliferation (Wei et al, 2009; Zhu et al, 2009) but there are also in vivo studies showing pro-LC activity of MSC treatment (Ramasamy et al, 2007).”
BackgroundMesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386
Mesenchymal stem cells enhance growth and metastasis of colon cancer
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Kodama, M., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25440 · Cited by 308
Cited by
Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., Sisto, F., Doglia, S. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.042 · Cited by 846
Self-citationMesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning
Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02837 · Cited by 572
Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic
Wu, H.-H., Zhou, Y., Tabata, Y., & Gao, J.-Q. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.019 · Cited by 288
Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99
Bosco, D. B., Kenworthy, R., Zorio, D. A. R., & Sang, Q.-X. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128511 · Cited by 50
Metadata
- Authors
- Pessina, A., Coccè, V., Pascucci, L., Bonomi, A., Cavicchini, L., Sisto, F., Ferrari, M., Ciusani, E., Crovace, A., Falchetti, M. L., Zicari, S., Caruso, A., Navone, S., Marfia, G., Benetti, A., Ceccarelli, P., Parati, E., & Alessandri, G.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-01-07
- Volume
- 160
- Issue
- 6
- Pages
- 766-778
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2139092985
- Cited by
- 84
- References
- 6
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia‐bearing mice. https://app.cochat.ai/papers/10.1111/bjh.12196
- The paper
- Pessina, A., Coccè, V., Pascucci, L., Bonomi, A., Cavicchini, L., Sisto, F., Ferrari, M., Ciusani, E., Crovace, A., Falchetti, M. L., Zicari, S., Caruso, A., Navone, S., Marfia, G., Benetti, A., Ceccarelli, P., Parati, E., & Alessandri, G. (2013). Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia‐bearing mice. British Journal of Haematology. https://doi.org/10.1111/bjh.12196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.